Systemic HypertensionSystemic Hypertension2075-082X2542-2189Intermedservice Ltd3354510.26442/2075082X.2019.2.000030Short CommunicationAcute heart failure and microRNANasonovaSvetlana NCand. Sci. (Med.)-MindzaevDzambolat RGraduate Student-ZhirovIgor VD. Sci. (Med.)izhirov@mail.ruTereshchenkoSergei ND. Sci. (Med.)-National Medical Research Center for CardiologyRussian Medical Academy of Continuous Professional Education15062019162424616042020Copyright © 2019, Consilium Medicum2019MicroRNA is a class of non-coding, single-stranded RNA 19-24 nucleotides in length, the main function of which is to inhibit the expression of protein-coding genes at the post-transcriptional level. It is known that microRNAs are an important pathogenetic link in the development of many diseases, including cardiovascular ones. Different levels of expression of these molecules in different pathologies make microRNAs potential diagnostic and prognostic biomarkers. Numerous studies confirm the fact of changes in the profile of microRNA expression in heart failure (HF). However, it is worth noting that the vast majority of these studies included patients with stable chronic HF, while the connection of these molecules with acute HF has received far less attention. Acute HF is the main cause of hospitalization for older patients. However, taking into account the low prognostic ability of existing biological markers of HF, the search for a new biological marker with a high prognostic significance is an important task of modern medicine. The article provides a brief overview of the research on the evaluation of diagnostic and prognostic abilities of a new potential of the biomarker in acute HF.acute heart failuremicroRNAa biomarkerdiagnosticsprognosisострая сердечная недостаточностьмикроРНКбиомаркердиагностикапрогноз[Weber J.A, Baxter D.H, Zhang S et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56: 1733-41.][Romakina V.V, Zhirov I.V, Nasonova S.N et al. Micro RNA as Biomarkers of Cardiovascular Diseases: Large Opportunities of Small Molecules. Cardiology 2018; 58 (1): 66-71. DOI: 10.18087/cardio.2018.1.10083][Givertz M.M, Teerlink J.R, Albert N.M et al. Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail 2013; 19: 371-89.][Maisel A.S, Richards A.M, Pascual-Figal D, Mueller C. Serial ST2 testing in hospitalized patients with acute heart failure. Am J Cardiol 2015; 115: 32B-37B.][Pascual-Figal D.A, Caballero L, Sanchez-Mas J, Lax A. Prognostic markers for acute heart failure. Expert Opin Med Diagn 2013; 7: 379-92.][Ouwerkerk W, Voors A.A, Zwinderman A.H. Factors influencing the predictive power of models for predicting mortality and/or heart-failure hospitalization in patients with heart failure. JACC Heart Fail 2014; 2: 429-36.][Rahimi K, Bennett D, Conrad N et al. Risk prediction in patients with heart failure. JACC Heart Fail 2014; 2: 440-6.][ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-200.][Bayés-Genis A, Lanfear D.E, de Ronde M.W.J et al. Pinto: Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patient. Eur J Heart Fail 2018; 20: 67-75.][Kochetov A.G, Lyang O.V, Gimadiev R.R et al. Expression of circulating microRNA in chronic heart failure in patients with cardiovascular pathologies. Lab Serv 2016; 1: 26-32. DOI: 10.17116/labs20165126-32][Masson S, Batkai S, Beermann J et al. Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure. Eur J Heart Failure 2018; 20: 78-85.][Tijsen A.J, Creemers E.E, Moerland P.D et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res 2010; 106: 1035-9.][Ellis K.L, Cameron V.A, Troughton R.W et al. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail 2013; 15: 1138-47.][Seronde M.F, Vausort M, Gayat E.J et al. GREAT Network. Circulating microRNAs and outcome in patients with acute heart failure. PLoS One 2015; 10: e0142237.][Bruno N, ter Maaten J.M, Ovchinnikova E.S et al. MicroRNAs relate to early worsening of renal function in patients with acute heart failure. Int J Cardiol 2016; 203: 564-9.][Ovchinnikova E.S, Schmitter D, Vegter E.L et al. Signature of circulating microRNAs in patients with acute heart failure. Eur J Heart Fail 2016; 18: 414-23.][Vegter E.L, Schmitter D, Hagemeijer Y et al. Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. Int J Cardiol 2016; 224: 231-9.][Vegter E.L, van der Meer P, Voors A.A. Associations between volume status and circulating microRNAs in acute heart failure. Eur J Heart Fail 2017; 19 (8): 1077-8.][Melman Y.F, Shah R, Danielson K et al. Circulating MicroRNA-30d Is Associated With Response to Cardiac Resynchronization Therapy in Heart Failure and Regulates Cardiomyocyte Apoptosis: A Translational Pilot Study. Circulation 2015; 131: 2202-16.][Xiao J, Gao R, Bei Y et al. Circulating miR-30d predicts survival in patients with acute heart failure. Cell Physiol Biochem 2017; 41: 865-74.][Van Boven N, Kardys I, van Vark L.C et al. Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure. Eur J Heart Fail 2018; 20: 89-96.][Жиров И.В., Кочетов А.Г., Засеева А.В. и др. МикроРНК в диагностике хронической сердечной недостаточности: состояние проблемы и результаты пилотного исследования. Системные гипертензии. 2016; 13 (1): 39-46.][Goren Y, Kushnir M, Zafrir B et al. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail 2012; 14: 147-54]